

Iasibon

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
N/0024	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	03/10/2022		PL	
IA/0023/G	This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters	11/07/2022	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

	and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method			
N/0022	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	10/01/2022		PL
IB/0021	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	17/11/2020	12/11/2021	SmPC, Labelling and PL
N/0020	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	03/04/2019	12/11/2021	PL
N/0019	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	28/06/2018	12/11/2021	PL
N/0018	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	18/10/2016	14/11/2016	PL
N/0017	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	21/07/2016	14/11/2016	PL

IAIN/0016	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	26/11/2015	14/11/2016	SmPC and PL	
R/0015	Renewal of the marketing authorisation.	23/07/2015	30/09/2015	SmPC and PL	Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Iasibon remains favourable. The CHMP is of the opinion that the renewal can be granted with unlimited validity.
IA/0014	A.7 - Administrative change - Deletion of manufacturing sites	11/05/2015	n/a		
IB/0012/G	This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	08/08/2014	08/07/2015	SmPC	
IB/0013	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	28/07/2014	08/07/2015	SmPC, Annex II and PL	

N/0011	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	07/04/2014	22/05/2014	PL	
IAIN/0010	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	16/10/2013	n/a		
II/0007	To add a new manufacturer of the active substance. B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is supported by an ASMF	27/06/2013	n/a		
IB/0009	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH	27/05/2013	22/05/2014	SmPC, Annex II, Labelling and PL	
N/0008	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	28/02/2013	22/05/2014	PL	
IB/0006	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	07/11/2012	n/a		
N/0005	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	18/05/2012	04/07/2012	PL	

N/0004	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	08/02/2012	04/07/2012	PL	
IB/0002/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH	14/12/2011	04/07/2012	SmPC, Annex II, Labelling and PL	
IAIN/0003/G	This was an application for a group of variations. C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH	08/12/2011	n/a		